CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 110 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04432090
NCT04432090Phase 2Completed

A Randomized, Placebo-controlled, Double-blinded Cross-over Study of the Pharmacologic Action of a GPR119 Agonist on Glucagon Counter-regulation During Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus

AdventHealth Translational Research Institute·interventional·Posted Jun 16, 2020·Updated Oct 17, 2024

In Brief

A Phase 2 clinical trial evaluating Placebo, Study Medication (MBX-2982), and 1 other intervention for Diabetes Mellitus, Type 1. Completed, enrolled 110 participants across 1 site.

Detailed Summary

The purpose of this study is to test if a specific research medication could increase the response to low blood glucose in people with type 1 diabetes. The response of the body to low blood sugar will be measured in healthy people as a reference point.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJun 16, 2020
Enrollment StartApr 21, 2021
Primary CompletionAug 12, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.0 years ago

Interventions

Placebodrug

Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)

Study Medication (MBX-2982)drug

Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)

No medication for this groupother

This group will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.